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ABSTRACT 
 
 
Wang, Tianxiu. M.S., Purdue University, May 2010. DNA Recognition and Cleavage by 
Phenyl-Benzimidazole Modified Gly-Gly-His-Derived Metallopeptides. Major Professor: 
Eric C. Long 
 
 
 Metallopeptides of the general form M(II)·Gly1-Gly2-His induce DNA strand scission 
via minor groove interactions. This peptide system can serve as a nucleic acid-targeted 
cleavage agent – either as an appendage to other DNA binding agents, or as a stand 
alone complex. In an effort to further our knowledge of DNA recognition and cleavage, a 
novel series of phenyl-benzimidazole modified Gly-Gly-His-derived metallopeptides was 
synthesized via solid phase methods and investigated. The new systems allow the 
formation of additional contacts to the DNA minor groove through the incorporation of a 
DNA binding phenyl-benzimidazole moiety, thus strengthening the overall binding 
interaction and further stabilizing the metal complex-DNA association. In addition, how 
Lys side chains and an amidinium group influence the efficiency of DNA cleavage was 
also studied. DNA cleavage studies suggested that the phenyl-benzimidazole-modified 
Gly-Gly-His metallopeptides possess enhanced DNA cleavage abilities. In particular, 
when amidines are placed on the benzimidazole moieties, these moieties appeared to 
play an important role in increasing the DNA cleavage activity of the metal complex, 
most likely through an enhanced electrostatic attraction to the DNA.
                                                                                                                                                                                                        1
    
 
CHAPTER1. INTRODUCTION: PEPTIDE-BASED SMALL MOLECULE-DNA 
 
INTERACTIONS 
 
 
 
1.1 Overview 
 
The DNA minor groove has been an important focus of chemical and biological 
studies ever since the elucidation of the structure of DNA and its role in the life cycle of a 
cell. In particular, much effort has been directed toward the development of synthetic 
DNA binding agents that target this DNA structure feature due to their potential as anti-
cancer, anti-viral, and antimicrobial drugs.1 Examples include the quinoxaline family2 of 
DNA intercalators, minor groove-binding molecules such as netropsin and distamycin,3-4 
and the bleomycin group5 of DNA cleavage agents. The binding of such compounds to 
the DNA minor groove usually involves a combination of weak intermolecular forces, 
such as electrostatics, van der Waals forces, and hydrogen bonding. As a general rule, 
minor groove binding compounds exert their biological impact through the disruption of 
normal cellular functions by binding at or near promoter regions of genes thus altering 
transcription;1 additionally, DNA minor groove binders can also disrupt DNA replication 
and, in the case of cleavage agents, lead to DNA damage.  
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The rational design of DNA binding agents often derives from known structural 
features of DNA-targeted natural products. Recently, for example, polyamides6 which 
were designed based on the natural products, netropsin and distamycin, have been 
demonstrated to target DNA selectivity through a “Pairing Code”.7 Additionally, 
benzimidazole derived ligands8-9 have displayed exceptional DNA binding abilities; these 
findings have broadened our vision with regard to potential future designs for DNA minor 
groove binding compounds. 
In addition to simply binding to the minor groove of DNA, clinically-employed 
antitumor agents such as the bleomycins can also induce DNA strand scission; the 
bleomycins cleave DNA through C4’-H abstraction10 when complexed with certain 
transition metals. Similarly, our laboratory has exploited M(II)·Gly1-Gly2-His-derived  
metallopeptides (Figure 1.1) as stand alone complexes to better understand amino acid- 
and peptide-nucleic acid recognition principles through DNA cleavage chemistry. In 
general, tripeptides can utilize a metal center to organize the linear peptide structure and 
to provide a platform that supports redox activity leading to DNA cleavage. 
 
 
                                
Figure 1.1. General structure of an M(II)·Gly1-Gly2-His-derived metallopeptide.  
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Given their amino acid compositions, the DNA targeting of these metallopeptide  
 
systems can be modulated by10: (1) the inclusion of certain amino acids and (2) the  
 
stereochemistry at each α-carbon10 leading to varied levels of DNA cleavage activity and  
 
site selectivity. Similar to the DNA cleavage chemistry of the bleomycins, direct DNA  
 
strand scission also occurs via C4’-H abstraction through an interaction between the  
 
activated metallopeptide complex and the floor of the minor groove.11 However, these  
 
metallopeptides alone are not tight DNA binders. Thus, a new design for Gly-Gly-His- 
 
derived metallopeptides was investigated in this thesis work. These new designs are  
 
comprised of two parts: (1) metallopeptides as studied previously10 and (2)  
 
benzimidazole moieties as used in many DNA ligand designs.12-14 Therefore, this series  
 
of compounds was generated with the aim of targeting DNA with higher efficiency. 
 
 
1.2 DNA Structure 
 
Ever since the structures of nucleic acids were revealed in the early 1950s, they 
have become popular targets for molecular recognition studies. Deoxyribonucleic acid 
(DNA), which acts as a genetic archive, is composed of nucleobases (purines, 
pyrimidines), deoxyribose sugars, and phosphates. In the primary DNA structure, 
phosphodiester-linked deoxyribose units form the backbone of each DNA strand and the 
double helix is made from two such strands winding helically around each other in an 
antiparallel fashion. The interior of the DNA helix is composed of stacked base pairs (A·T, 
G·C) which are attached to the C1’ on the sugar rings via an N-glycoside bond and 
interact with each other via hydrogen bonds to form Watson-Crick base pairs (Figure 
1.2). 
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Figure 1.2. Primary structure of DNA. 
 
It is well-known that DNA adopts three main conformations, the A-form, B-form and 
Z- form (Figure 1.3). B-form DNA is the most common and exists under physiological 
conditions. Generally speaking, the double helical structure of B-DNA conforms to the 
features of canonical Watson-Crick DNA: a right-handed double helix with approximately 
ten nucleotides per helical turn. Compared to B-DNA, A-DNA is wider and has base 
pairs inclined to its helix axis instead of being perpendicular to it. Z-DNA, on the other 
hand, is a left-handed helix whose repeat units are dinucleotides and exhibit a 
characteristic “zigzag” backbone.15 The conformation DNA adopts depends on the 
hydration level, DNA sequence and chemical modification of the bases.16 Moreover, the 
DNA molecule can adapt itself to the environment and therefore, it can exhibit several 
different conformations in different segments.15 
                                                                                                                                                                                                        5
    
 
 
Figure 1.3. The structures of A, B, Z-DNA (from left to right). 
 
Due to the asymmetry of the N-glycoside connection to the Watson-Crick base pairs, 
there are two unequally sized grooves formed in B-form DNA, designated the major and 
minor grooves. As they are named, the major groove is wide, while the minor groove is 
narrow (Figure 1.4 A).17 The edges of base pairs constitute the floor of the grooves and 
present different hydrogen bonding acceptor and donor patterns to a possible ligand. 
Indeed, a closer look at the grooves of DNA reveals a basis for DNA sequence 
recognition mechanisms (Figure 1.4 B). For the major groove, the edges of A·T and G·C 
base pairs provide three possible hydrogen bonding sites: there are two hydrogen bond 
acceptors (guanine-N7 and guanine-O4) and one hydrogen bond donor (cytosine-N4) 
from G·C pairs; similarly, two hydrogen bond acceptors (adenine-N7 and thymine-O4) 
and one hydrogen bond donor (adenine N6) are presented by A·T pairs. In addition, the 
methyl group of T provides a potential van der Waals interaction. Large molecules, such 
as proteins which have more functional groups, generally identify bases in the major 
groove of DNA leading to their site-specific DNA binding.  
                                                                                                                                                                                                        6
    
 
  
                                A                                                B 
Figure 1.4. Three dimensional structure of B-DNA (A); Watson-Crick base pairs (B). 
 
In comparison, the minor groove presents fewer functionalities for nucleobase 
recognition. There are only three accessible hydrogen bonding sites at a G·C base pair 
and two hydrogen bond acceptors at adenine-N3 and thymine-O2 of an A·T site. 
Although it seems that the edge of G·C is more favorable than those of A·T, several 
studies have demonstrated that many binding agents prefer A·T sites over G·C sites, 
suggesting that hydrogen bonding is not a dominant factor for sequence discrimination 
of the minor groove. Indeed, electrostatic potential also plays an important role: a run of 
A·T base pairs has the greatest negative potential at the floor of the minor groove, 
whereas, G·C sequences have the greatest positive potential.1 This likely explains why 
cationic agents prefer to bind A·T rich regions. Moreover, X-ray studies suggest that the 
exocyclic N2 amino group of guanine is often a steric block to minor groove binding.18 As 
a consequence of the structure of the narrow minor groove, low molecular weight ligands 
with specific structures can be accommodated. 
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In summary, much effort and progress has been made to further our understanding  
 
of the structural features of DNA biomacromolecules. The numerous binding sites  
 
displayed on the surface of DNA and the knowledge of known binders (proteins and low  
 
molecular weight compounds) continuously inspire scientists to design and construct  
 
novel molecules with enhanced DNA affinity and specificity. Given the topic of this thesis,  
 
the following sections will focus on low molecular weight ligand-DNA interactions located  
 
in the minor groove.  
 
 
1.3 DNA-Small Molecule Interactions 
 
In general, a combination of electrostatic interactions, hydrogen bonding, 
hydrophobic interactions, wan der Waals contacts, and steric forces combine to 
influence the mode of ligand binding.19 Koshland proposed the ‘induced fit’ model which, 
when applied to DNA recognition, suggests that both the DNA helix and a potential 
binder might experience some conformation changes upon their interaction. Distortions 
of DNA structure (bending, unwinding, lengthening, etc.) are observed in many ligand-
DNA complexes. For example, intercalation into DNA usually causes significant local 
structural changes of the duplex; while groove binding, at times, can significantly perturb 
the DNA structure.19  
The binding of small molecules to the minor groove can also lead to DNA cleavage.  
 
This process typically involves one of the following pathways: (1) oxidation at the  
 
deoxyribose sugar ring by abstracting a hydrogen atom which results in the  
 
fragmentation of the sugar; (2) modification of a nucleobase; and (3) the hydrolysis of  
 
the phosphodiester backbone.20 In all these cases DNA polymer strand fragmentation  
 
can occur. 
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1.3.1 DNA Intercalators 
 
Intercalation occurs when a planar, aromatic moiety slides between two adjacent 
stacked DNA base pairs.21 Intercalation changes the base pair spacing from 3.4 Հ to 6.8 
Հ and induces local structural changes to the DNA such as helix unwinding and B-form 
to A-form transitions (Figure 1.5). These changes can alter DNA-based processes. 
Therefore, some intercalators such as ethidium bromide (Figure 1.6) are also potent 
mutagens. Similarly, due to their tight association with DNA, many intercalators have 
clinical efficacy and have been used as chemotherapeutic treatments to inhibit DNA 
replication in rapidly growing cancer cells. 
          
Figure 1.5.  DNA intercalation. 
 
Several intercalators such as ethidium bromide (Figure 1.6) and thiazole orange are 
used as non-specific intercalating agents that display enhanced fluorescence upon DNA 
binding. The intense fluorescence of these agents upon DNA binding derives from 
electronic perturbations in the ligand and result from the release of fluorescence 
quenching water as well as the stabilization of overlapping ߨ-systems. The application of 
fluorescent intercalators to examine the DNA binding characteristics of other molecules 
is particularly useful.22-23 in addition, ethidium bromide is employed to visualize the 
presence or the location of DNA fragments in agarose gel electrophoresis.24-25  
                                                                                                                                                                                                        9
    
 
 
Figure 1.6. Structure of ethidium bromide. 
 
Along with monointercalators such as ethidirm bromide, there are also many natural 
bisintercalators, for example, the quinoxaline antibiotics (echinomycin) (Figure 1.7).2 
Beyond bisintercalators, synthetic efforts have led to tris- and tetraintercalators or even 
polyintercalators to cover longer DNA sequences.26 Although many intercalators do not 
exhibit high levels of DNA sequence site selectivity, studies do indicate that they 
generally favor insertion into G·C rich regions.27 This preference points out that ߨ-ߨ 
overlap plays an important role in DNA Intercalation. 
 
                                A                                                                    B 
Figure 1.7. Chemical structures of a monointercalator (A) and a bisintercalator (B). 
 
1.3.2 DNA Minor Groove Binders 
In addition to intercalative binding, the 3D structure of DNA duplexes also allow 
contacts in their major and minor grooves. As a general rule, protein recognition occurs 
                                                                                                                                                                                                        10
    
 
mainly through the major groove while small molecules generally prefer minor groove 
binding. Additionally, many minor groove binders exhibit an A·T preference. In order to 
better understand favored binding in the DNA minor groove, several structural factors 
must be taken into consideration as discussed below. 
The electrostatic potential along a DNA sequence is sequence-dependent, with a 
run of A·T base pairs having a greater negative potential than a run of G·C base pairs at 
the floor of the minor groove. This is due to the presence of electro-rich thymine O2 and 
adenine N3 (Figure 1.8).1 This feature makes A·T rich sequence more attractive to low 
molecular weight agents which carry positive charges. Agents such as netropsin and 
distamycin represent classic examples of minor groove binders and contain at least one 
positively charged moiety. Similarly, synthetic minor groove binding ligands are typically 
designed to incorporate at least one positively charged moiety to improve binding affinity 
                         
                                              A                                            B 
Figure 1.8. View of the electrostatic potential surface of DNA, where red represents 
positive potential. The narrow A·T minor groove (A); The wide G·C minor groove (B). 
 
As mentioned before, DNA groove widths vary along the helix. G·C rich regions in 
the minor groove are about 6 Հ wider than the corresponding A·T rich regions. The 
                                                                                                                                                                                                        11
    
 
narrowed groove width in A·T rich regions can provide hydrophobic contacts for flat, 
curved small molecules.28 Also, the narrowed A·T rich minor groove can align a small 
molecule in such a way as to permit the hydrogen bonding groups to be exposed directly 
to the floor of the groove where they can interact with hydrogen bond acceptors.1 In 
addition, the curvature of the A·T rich minor groove complements the overall shape of 
many small binding ligands very well, whereas the floor of G·C tracts have 
discontinuities arising from the presence of the guanine exocyclic 2-amino group.1 
The following section introduces several DNA minor groove binding molecules.  
 
Information obtained from their study can help further our knowledge of DNA recognition  
 
principles and guide the design of next generation agents. 
 
 
1.3.2.1 Netropsin and Distamycin  
 
Netropsin and distamycin represent extensively studied natural products derived 
from Streptomyces netropsis  and Streptomycete distallicus29 and are well-known for 
their A·T selective DNA binding properties. As shown in Figure 1.9, the molecules are 
crescent shaped bi- and tripeptides containing pyrrole rings linked by amide bonds.30 So 
far, over 20 high-resolution structures of netropsin-DNA and distamycin-DNA complexes 
obtained by NMR and X-ray crystallography have been reported.31,3,4 Also, quantitative 
footprinting methods have been employed to analyze their sequence preferences.32 
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Figure 1.9. The structures of netropsin and distamycin. 
 
These investigations have revealed the detailed mechanisms by which these 
antibiotics bind to and recognize double-stranded DNA.33 As noted, both netropsin and 
distamycin possess propylamidinium groups at their C-termini and netropsin possesses 
a guanidinium at its N-terminus (or with distamycin a formylated N-termini). These 
positively charged tails provide electrostatic attractions to DNA and facilitate the delivery 
of the ligands to the electronegative minor groove. Conceptually, the binding process 
may thus be divided into two parts. First, the groove binding agents undergo a 
hydrophobic transfer from bulk solution into the DNA minor groove,34 localization in the 
minor groove then promotes the formation of short range affinity-enhancing interactions: 
once in the minor groove, van der Waals attractions and hydrogen bonds are formed 
between the ligands and the floor of minor groove. The inherent crescent shape of these 
drugs also complements the minor groove curvature very well, which leads to deep 
penetration and close van der Waals contact. Moreover, the amide hydrogens of the N-
methypyrrolecarboxamides of these agents form bifurcated hydrogen bonds with the N3 
of adenine and the O2 of thymine on the floor of minor groove.30 This favored interaction 
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between the amide hydrogens and the A·T base pair edges results in preferential A·T 
binding. An illustration of the hydrogen bonds formed between netropsin and the minor 
groove is presented in Figure 1.10.35    
 
 
                 
Figure 1.10. Netropsin-minor groove hydrogen bonding interactions. 
 
1.3.2.2 Polyamides 
Given the modular nature and DNA binding selectivities of netropsin and distamycin, 
many minor groove binders have been designed based on the architecture of these lead 
compounds. Initially, the strategy intended to extend the length of these groove binding 
agents in hopes of targeting longer DNA sequences.34 However, simply connecting 
additional N-methypyrrolecarboxamide residues together or joining two netropsin 
molecules doesn’t make them efficient DNA binders because of their length. The second 
phase synthetic effort involved replacing the carboxamide bond in netropsin or 
distamycin with shorter keto or amino linkages.34 This new strategy also introduced 
imidazole, furan rings and other heterocycles to recognize G·C tracts. Based on these 
changes, a family of compounds called lexitropsins was synthesized by Lown and 
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coworkers.36-39 The ability of lexitropsins to read G·C base pairs embedded in A·T rich 
regions on DNA arises from the hydrogen bond acceptor groups located on these 
heterocyclic substitutions, as illustrated in Figure 1.11.36  However, lexitropsins showed 
reduced overall DNA binding affinity and relatively low G·C specificity. 
 
 
Figure 1.11. Proposed model of the interaction of a lexitropsin with guanine residues in 
DNA. 
  
Following the above work, the discovery40 in 1989 that the minor groove of A·T rich 
DNA could accommodate two distamycin molecules associated in an antiparallel side-
by-side orientation inspired the design of dimeric systems.7 Shortly after that, NMR 
studies demonstrated that two synthetic polyamides can fit side-by-side into DNA minor 
groove to permit both to interact with base pairs via hydrogen bonding (Figure 1.12).41-42 
In addition, it was found that the sequence selectivity and geometry of such a ligand-
DNA complex could be optimized by choosing appropriate pairs of ligand molecules with 
complementary recognition properties.34 Thus, a new dimer system could be engineered 
to distinguish G·C base pairs from C·G base pairs, and A·T base pairs from T·A  base 
pairs, the latter could be achieved simply by utilizing the lone electron pairs on the O2 of 
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thymine. Moreover, covalently linking of two DNA reading polyamides avoids the 
ambiguity of slipping within the minor groove and ‘locks’ individual ring pairings in a 
predictable manner.42 
   
Figure 1.12. Structures of polyamides bound to DNA: a) 2:1 motif; b) 1:1 motif. 
 
Based on the above findings, Dervan et al. have developed a series of synthetic 
polyamide containing pyrrole-imidazole (Py-Im) moieties that can specifically recognize 
virtually any DNA sequence.6 These DNA-binding polyamides mainly consist of three 
central blocks, N-methylimidazole (Im), N-methypyrrole (Py), and N-methyl-3-
hydroxypyrrole (Hp) to form crescent ‘hairpin’ molecules to target DNA sequences 
(Figure 1.13). Further, the introduction of a bulkier 3-hydroxypyrrole brings steric 
destabilization of binding to adenine and allows the hydrogen donor penetrating into the 
groove to interact with O2 of thymine, thus discriminating A·T base pairs from T·A base 
pairs. Therefore, all four base pairs can be identified: Im/Py targets G·C; Py/Im targets 
C·G; Hp/Py targets T·A; Py/Hp targets A·T, this is referred to as the Pairing Code (Figure 
1.13). Studies also found that polyamides containing an N-terminal formamido group 
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displayed enhanced DNA binding ability.43-44 As a result, this new generation of 
polyamides extended DNA sequence recognition sites up to 16 base pairs.45 
Furthermore, hairpin polyamides can exhibit affinities and specificities for DNA 
comparable with transcription factors and other DNA binding regulatory proteins.46  
 
Figure 1.13. Illustration of Dervan’s “Pairing Code”. 
 
More recently, efforts have been devoted to developing heterocycles that are 
capable of cooperatively pairing with each other to recognize DNA base pairs in the 
minor groove.47 Towards this end, the incorporation of fused heterocycles such as 
benzimidazole has been investigated. Notably, benzimidazoles appear in the structures 
of some DNA minor groove binders, for example, Hoechst 33258, which can recognize 
sequences such as 5’-WGGGGW-3’ with high affinity.48 The benzimidazole moiety 
integrated into the hairpin polyamide templates presents hydrogen donating groups to 
the floor of DNA minor groove, thus maintaining similar DNA recognition properties. In 
addition, hydroxybenzimidazole (Hz) can be used to replace hydroxypyrrole which 
degrades over time in the presence of acid or free radicals.  
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Certain designed polyamides are able to influence gene expression. An eight ring  
 
hairpin Py-Im polyamide which binds six base pairs was reported to inhibit the binding of  
 
the transcription factor TFIIIA, thus suppressing the transcription of 5S genes.49 In  
 
another study, androgen-induced expression of prostate-specific antigen and several  
 
other androgen receptor (AR)-regulated genes are inhibited by cell-permeable  
 
polyamides.50 Polyamides offer an alternative approach to antagonizing AR activity. In  
 
addition, the programmability of polyamides may allow more powerful inhibition of  
 
predetermined target genes.51                                                                                  
 
 
1.3.2.3 Benzimidazole-Based Systems 
 
Hoechst 33258 is comprised of two benzimidazole groups linked in a head-to-tail 
manner with a phenol head and N-methylpiperazine tail (Figure 1.14). It is primarily used 
as a fluorescent DNA stain, which can be excited by ultraviolet light at around 350 nm to 
emit a blue/cyan fluorescence light at around 461nm upon binding to dsDNA. DNA 
footprinting and biophysical studies have shown that Hoechst 33258 binds selectively to 
A·T sequences, with a binding site size of 4-5 bases.1 As a DNA binder, Hoechst exhibits  
antitumor activity31 and has been in phase I/II clinical trials against pancreatic 
carcinomas;52 however, this candidate was abandoned due to its toxicity.1 
 
 
Figure 1.14. Structure of Hoechst 33258. 
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Crystal structure analyses and NMR studies53-54 of Hoechst 33258 complexed to 
various oligonucleotide duplexes have revealed the binding mode of the drug in the DNA 
minor groove. The ligand adopts a crescent conformation and makes extensive van der 
Waals contacts with the backbone and base atoms; the planar benzimidazole moiety,55 
orients parallel to the groove direction and forms bifurcated hydrogen bonds to the A·T 
base pairs in a fashion very similar to that of netropsin;56 the bulky N-methypiperazine 
ring of the drug, most of the time, is located in a wider G·C region without participating in 
a hydrogen bond.53,57  
A number of Hoechst 33258 analogues that bind certain extended A·T sequences in 
DNA8-9 have been designed and synthesized (Figure 1.15). The study of these 
compounds introduces a new point of view on small molecule-DNA interaction principles, 
one which is slightly different from the canonical models exemplified by netropsin and 
distamycin.  
 
 
        
 
Figure 1.15. Structures of some benzimidazole derived DNA binding agents. 
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While most minor groove binder designs focus on the development of concave 
inner-faced ligands which complement the shape of the minor groove floor,9 as shown in 
Figure 1.15, none of the three compounds satisfies this criterion despite their good DNA 
binding properties. For example, with RT29, the diphenyl ether moiety is over-curved 
compared to agents such as netropsin and distamycin. Consequently, these flat 
compounds should fail to position their functional groups in an effective way for 
hydrogen bonding in the minor groove of DNA. Surprisingly, on the contrary, the ligands 
exhibit enhanced binding affinity relative to their parent compound Hoechst 33258.8-9 To 
explain their binding, X-ray studies revealed that the ligands undergo conformational 
changes, such as twists and distortions to follow the helical curvature of the minor 
groove and place the functional groups in closely optimized positions for interaction with 
DNA.8 Additionally, water molecules play an important role in stabilizing drug-minor 
groove interactions. The drug molecules recruit water molecules at their termini to bridge 
with additional base pair edges.   
Another structural alteration involved the introduction of cationic amidinium groups 
into the design. In addition to making the ligands attractive to the DNA minor groove, 
amidinium nitrogens are also observed to participate in hydrogen bonding with A·T base 
pairs in the minor groove.35,58-59 In fact, aromatic diamidines have drawn intensive 
attention due to their broad-spectrum antimicrobial activities which are believed to result 
from the minor groove binding of these type of compounds.60 In short, effective subunit 
phasing upon DNA minor groove binding, in combination with extra hydrogen bonds 
established from the amidine groups of these benzimidazole-derived compounds make 
them strong additions to any DNA binding ligand designs. 
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1.3.3 DNA Cleavage by Natural Products 
Considerable effort has been put into studying and designing ligands that not only 
bind DNA, but are also capable of modifying the DNA helix. Among such agents, the 
bleomycins are a family of glycopeptide derived natural products first isolated from 
Streptomyces verticillus by Umezawa et al. in 1966.5 Soon after their discovery, 
bleomycins were used in the treatment of several neoplastic diseases including 
squamous cell carcinomas, malignant lymphomas and ovarian cancer.61-62 The 
bleomycin group contains over 200 closely related compounds that differ only in their 
sugar moieties and positively charged C-termini.61 When used as an anti-cancer drug, 
the administered forms are primarily bleomycin A2 and B2 and the therapeutic utility of 
the bleomycins is believed to derive from their ability to mediate DNA strand scission, a 
transformation that is metal ion and oxygen dependent.62 Recent studies of bleomycin 
have focused on their structures and DNA binding selectivity. 
As presented in Figure 1.16, the structure of bleomycin can be separated into three 
regions: (1) the pyrimidine, ߚ-amino alanine and ߚ-hydroxyimidazole moieties, which 
constitute the core metal-binding peptide that is responsible for DNA cleavage and site 
recognition; (2) the positively charged bithiazole moiety that increases DNA binding 
affinity; and (3) the glucose and carbamoylated mannose carbohydrate residues, which 
are believed to aid in the cellular uptake of the drug and increased stabilization upon 
DNA binding. The functions of these domains were evaluated by studying several 
bleomycin analogues: studies demonstrated that the lack of sugar, peptidyl linker or 
bithiazole tail does not affect the sequence-selectivity of these compounds, which 
supports the notion that the metal binding domain plays an important role in binding to 
DNA.63 In addition, it was proposed that the drug-DNA binding is initiated via bithiazole  
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intercalation in cooperation with alignment of the metal binding domain on the floor of the 
minor groove.61 Thus, the binding affinity and cleavage selectivity derives from the metal 
binding domain in cooperation with the bithiazole tail.                                       
          
Figure 1.16. Structure of bleomycin A2. 
 
The best characterized property of bleomycin is certainly its ability to mediate the 
degradation of DNA substrates.64 This process has been established by analyzing 
fragments from various bleomycin-DNA interactions. Bleomycin induced DNA 
degradation requires the presence of a redox-active metal ion such as Fe(II), as well as 
molecular oxygen.65 Upon their combination, the formation of an activated complex 
(Figure 1.17) leads to direct DNA strand scission at 5’-GC or 5’-GT steps which were 
identified as the preferential DNA cleavage sites of bleomycins via a C4’-H abstraction 
pathway.61 Along with DNA cleavage, the bleomycins also mediate lipid peroxidation, 
membrane damage and oxidative RNA degradation.61,66 
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Figure 1.17. Structure of the bleomycin metal binding domain. 
 
In addition to Fe(II), other transition metals including Cu, Co, Mn, Ni, Ru, V and Zn 
 
also bind to bleomycin as cofactors.61 The resultant metallobleomycins are not only 
 
structurally different from each other, but also have different DNA recognition and 
 
modification properties.62 Given its metallopeptide core metallobleomycin served as a  
 
control in our investigations. 
 
 
1.4 Metallopeptide-DNA Interactions 
 
 
 
1.4.1 Gly-Gly-His-Derived Metallopeptides 
Metallopeptides of the general form Cu(II)·or Ni(II)·Gly-Gly-His, where Gly can be 
any α-amino acid, have historically served as models of the Ni(II) and Cu(II) transport 
domains of the serum albumins.67 With Cu(II) or Ni(II) at physiological pH, peptide 
complexation occurs through chelation of the histidine imidazole nitrogens, two 
intervening deprotonated amide nitrogens and the terminal α-amine, as shown in Figure 
1.18.10 This peptide was found to bind Cu(II) and Ni(II) in a 1:1 complex with extremely 
high affinity (KD values on the order of 10-16 M). For our purposes, the square-planar 
structure which is somewhat similar to the metal binding domain of the 
metallobleomycins, can generate oxidants that cause DNA strand scission. Indeed, it 
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has been reported that Cu(II)·Gly-Gly-His + ascobate induced DNA strand scission and 
showed cytotoxic activity against Ehrlich ascites tumor cells.68   
      
Figure 1.18. Structure of Ni(II)·Gly-Gly-His. 
 
1.4.2 DNA Cleavage Analyses 
Our research group determined that when activated with equimolar Oxone (KHSO5), 
magnesium monoperoxyphthalic acid, or hydrogen peroxide at physiological pH, 
Ni(II)·Gly-Gly-His induced selective, direct DNA strand scission via a nondiffusible 
oxidant, likely a peptide-bound Ni(III)-HO· or Ni=(IV).69 Furthermore, our laboratory also 
identified the DNA products resulting from metallopeptide cleavage. It was found that the 
5’- and 3’- termini formed were consistent with the chemistry of C4’-H abstraction.10 Thus, 
the metallopeptides are not only structurally similar to the DNA binding domain of 
Fe(II)·bleomycin, but also parallel the activity of it, that is, causing DNA degradation by 
C4’- hydrogen abstraction in the minor groove via two different pathways (Figure 1.19): 
(1) formation of keto-aldehyde abasic lesions and loss of free nucleobase, indicating the 
formation of a C4’-hydroxyl intermediate and (2) direct DNA strand scission and the 
release of 5’-phosphorylated termini, 3’-phosophoroglycolate termini and nucleobase 
propenals, suggesting the formation of a C4’-hydroperoxyl intermediate.10,69       
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Figure 1.19. Pathways of deoxyribose-based DNA degradation by Ni(II)·Gly1-Gly2-His 
metallopeptides. 
 
 
To further understand metallopeptide-DNA interactions, Lys and Arg substituted 
tripeptides that impart a net positive charge to the system for an increased electrostatic 
interaction with the DNA backbone, were investigated. In particular, peptides with Lys or 
Arg incorporated into the Gly1 position (Figure 1.20 A) were found to have DNA cleavage 
activities at least three-fold higher than that of the neutral Ni(II)·Gly-Gly-His template and 
become highly focused to A·T rich regions.10 The DNA-binding mode of Cu(II)·Xaa-Gly-
His metallopeptides (where Xaa is Gly, Lys or Arg) has also been characterized by DNA 
fiber EPR spectroscopy and molecular modeling. These studies revealed that the metal 
complex binds with its equatorial plane oriented 40Ԩ relative to the DNA helix axis in the 
minor groove.70 Recently, one- and two- dimensional NMR methodologies and molecular 
simulations were carried out using the A·T rich Dickerson oligonucleotide, 
d(CGCGAATTCGCG)2, and Ni(II)·Arg-Gly-His in an effort to more precisely define the 
DNA association characteristics of Gly-Gly-His derived metallopeptides.67 As presented 
in Figure 1.20,67 the results indicated that the His imidazole N-H, the N-terminal peptide 
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amine and the Arg side chain are major determinants of minor groove recognition by 
functioning as hydrogen bond donors to the O2 of thymine or N3 of adenine nucleotides.  
    
                           A                                                                                B 
Figure 1.20. Structures of Ni(II)·Arg-Gly-His and Ni(II)·Lys-Gly-His (A); Minor groove 
binding by Ni(II)·Arg-Gly-His with the O2 of thymine and N3 of adenine (B). 
 
Furthermore, the average structure of Ni(II)·L-Arg-Gly-His produced from molecular 
dynamic simulations was found to have a surprising correspondence with netropsin and 
Hoechst 33258 (upon structural studies with the same AATT oligonucleotide) (Figure 
1.21), suggesting that these low molecular weight metallo-peptides can mimic natural 
drug structural strategies for DNA minor groove binding. 
 
 
Figure 1.21. Comparison of the structure of Ni(II)·L-Arg-Gly-His to netropsin and Hoechst 
33258, arrows indicate locations of potential hydrogen bond donating groups. 
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1.4.3 Determination of DNA Cleavage 
An established plasmid DNA cleavage assay71 was employed to characterize the 
overall cleavage activity of these metallopeptides. In such a study, supercoiled Form I 
DNA is converted to nicked circular Form II DNA, which can be further cleaved to form a 
linear Form III DNA as depicted in Figure 1.22. The three topological forms of DNA may 
be separated via horizontal agarose gel electrophoresis based upon their different 
migration rates through the gel. As a result of their different shapes, the compact Form I 
migrates the fastest;  the bulky nicked circular Form II displays a much slower rate 
compare to Form I; and the linear Form III migrates with a rate intermediate between 
those of Form I and Form II. 
 
 
Figure 1.22. Topological forms of plasmid DNA. 
 
1.5 Plan of Study 
   The research described herein focused on the design, synthesis and study of 
novel DNA-interactive phenyl benzimidazole–metallopeptide ‘hybrids’. In particular, we 
sought to enhance the DNA binding ability of our original metallopeptides through further 
modification. In light of the synthesis of benzimidazoles on solid supports,72 we chose to 
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modify our basic metallopeptide structure through addition of a phenyl benzimidazole 
(with or without an amidine end) moiety through solid phase synthesis. In addition, 
positively charged Lys was used in the Gly2 position in an effort to maintain a positively-
charged metallopeptide domain. As depicted in Figure 1.23, our effort led to three 
different metallopeptide systems containing phenyl-benzimidazole moieties: (1) a neutral 
system just like the parent M(II)·Gly-Gly-His metallopeptide; (2) singly positively charged 
systems with an amidinium group on the benzimidazole moiety or a Lys side chain 
substitution within the metallopeptide domain; and (3) systems with two positive charges 
provided by both amidine and Lys side chains. DNA cleavage studies, carried out using 
these phenyl-benzimidazole modified Gly-Gly-His-derived peptides, revealed that the 
phenyl-benzimidazole moiety (with or without amidinium groups) led to increased DNA 
strand scission activity and that Lys substitutions can also facilitate the activity of the 
whole system.  
 
N
N
N
N
HN
NH2
O
OHN
C
O
O
N
H
N
M2+
H2N
H2N NH3  
Figure 1.23. Structure of a potential phenyl-benzimidazole modified Gly-Gly-His-derived 
metallopeptide. Substitutions used are in red. 
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CHAPTER 2. DESIGN AND SYNTHESIS OF PHENYL-BENZIMIDAZOLE- 
                                               
MODIFIED METALLOPEPTIDES 
 
 
 
2.1 Design Considerations 
 
A novel DNA recognition/cleavage system was designed based on the  
 
combination of a phenyl-benzimidazole moiety and the DNA cleavage properties of  
 
Gly-Gly-His-derived metal binding tripeptides. Given the minor groove targeting of  
 
phenyl-benzimidazole and M(II)·Gly-Gly-His derived metallopeptides, it is predicted  
 
that these two moieties should act synergistically and lead to increased DNA  
 
interaction and enhanced DNA cleavage. 
 
 
2.1.1 (ߜ)-Orn-Gly-His Strategy 
 
Although the Gly-Gly-His tripeptide represents a simple yet competent DNA 
cleavage model, the role played by the terminal amine functionality of this tripeptide unit 
limits the corporation of this metal binding domain to the amino-terminus of a 
polypeptide.1 Several years ago our laboratory developed a method which permits the 
placement of a Gly1-Gly2-His metal binding domain at any location within a linear 
synthetic peptide chain while preserving its metal-binding, electronic and catalytic 
properties2. The strategy involved introducing an N ߜ-Fmoc-N α-Boc-ornithine into the 
amino-terminal Gly1 position during solid-phase synthesis. This substitution then permits 
continued synthesis via the deprotected ߜ-amino group of ornithine.2 As illustrated in 
Figure 2.1, the design leaves the α-amino group of Orn free to participate in M(II) 
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complexation as it would in a tripeptide alone. Given the ability to link the ߜ amino group 
of a resin bound Orn to other functionalities2, we exploited this position for linking and 
construction of phenyl-benzimidazole moieties with and without additional amidine 
modifications. Our strategy led to metallopeptide-phenyl-benzimidazole hybrids as shown 
in Figure 1.23. 
 
  
Figure 2.1 The structure of M(II)·(ߜ)-Orn-Gly-His with the ߜ-amino group (in red) ready for 
further coupling. 
 
2.1.2 Amidinium Benzimidazole Solid Phase Synthesis 
As mentioned in Chapter 1, several studies have demonstrated that the 
benzimidazole moiety of some well-documented DNA binding molecules supports an 
efficient and site-selective DNA association. In addition, aromatic amidines have been 
prepared as arginine side-chain mimetics due to their favorable electrostatic properties.3 
Thus, as mentioned above, we included amidinium benzimidazole moieties in our design 
with the aim of obtaining better DNA-interactive systems. 
The solution phase synthesis of benzimidazoles has been reported in good yields4-5 
via 1,4-benzoquinone facilitated oxidative coupling of aldehydes with an appropriate 
3,4-diaminobenzamidine at high temperature.6 Recently, a solid-phase synthesis of 
benzimidazole by making phenylenediamine on Wang resin and then coupling it to 
soluble imidate was reported.7 Also, benzimidazoles can be prepared by coupling 
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4-carboxybenzaldehyde to Wang resin, followed by condensation with 
phenylenediamines in solution.8 These reactions can be catalyzed by 1,4 dihydroquinone 
at elevated temperature (130Ԩ) to drive the reaction to completion.8  
The introduction of amidinium groups onto benzimidazoles in solution phase  
 
synthesis often utilizes substituted aromatic amidines in the coupling step,9-11 such as the  
 
frequently used starting material 3,4-diaminobenzamidine, which can be obtained from  
 
the method of Fairley et al.12 An alternatively strategy6,13 involves the use of the precursor  
 
3,4-diaminobenzonitrile to form a benzimidazole ring, followed by appropriate  
 
conversions and reductions. Routes leading to efficient solid phase amidinium  
 
benzimidazole synthesis described herein have been explored. Our design involves a  
 
combination of several reported approaches. 
 
 
2.1.3 Amidinium Benzimidazole Tripeptide Conjugates 
 
In light of the (ߜ)-Orn-Gly-His solid phase synthesis strategy, a series of 
benzimidazole-tripeptide conjugates were generated. The basic structure of our new 
design is shown in Figure 2.2. 
 
 
 
Figure 2.2. Structure of an amidinium-containing benzimidazole-tripeptide conjugate, 
where Gly2 can be substituted by Lys. 
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2.2 Synthesis 
A general synthesis scheme leading to our final products is given in Figure 2.3. All 
syntheses started with Rink amide resin. This resin generates peptides with amide 
termini upon resin cleavage, thus eliminating the negative charge of a carboxylate; the 
tripeptides were thus synthesized with C-terminal amides to produce an overall charge 
neutral complex, and to prevent decarboxylation upon metal binding.14 Well-established 
solid-phase peptide synthesis (SPPS) protocols were used to construct the peptide core 
of the modified conjugates (Figure 2.4). All peptide couplings were confirmed by negative 
Kaiser tests. Two grams of starting Rink resin was used and split several times to obtain 
the final products. Peptides 1 and 3 (0.5 g on resin) (Figure 2.3), served as controls and 
standards for comparison throughout this study. The crude yields obtained were about 95% 
and the compounds were characterized by LC/MS at (m+H)+: 1 m/z 269, 3 m/z 340 (the 
predicted m/z are 268.13 and 339.21, respectively). As mentioned before, upon dipeptide 
synthesis, (ߜ)-ornithine was then coupled to the solid support to expand the functionalities 
of the metallopeptides. 
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Figure 2.3. Synthetic scheme for the generation of phenyl-benzimidazole modified 
compounds. 
 
 
 
 
Figure 2.4. Solid-phase amino acid coupling to Rink amide resin. 
 
After coupling all the three amino acids to the resin, 1,4-carboxybenzaldehyde was 
attached to the ߜ-amino terminus of ornithine in a similar fashion to obtain compounds 2 
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and 4. Longer reaction times and excess starting materials were used to drive the 
reaction to complete (Figure 2.5). Resin-bound (ߜ)-Orn-Gly2-His was mixed with 5 equiv. 
starting materials at room temperature with nitrogen bubbling overnight. Completions of 
couplings were confirmed by negative Kaiser test. 
 
 
 
Figure 2.5. Solid-phase coupling of carboxybenzaldehyde to resin-bound 
(ߜ)-Orn-Gly2-His (where Gly2 can be substituted by Lys). 
 
 
2.2.1 Compounds without an Amidinium Group (BI-(ߜ)-Orn-Gly2-His) 
 
Benzimidazoles have been synthesized in good yields in solution via 
1,4-benzoquinone facilitated oxidative coupling of aldehydes with an appropriate 
3,4-diaminobenzene at high temperatures.15 We employed this procedure in our 
solid-phase synthesis of benzimidazoles. Resin-bound compounds 2 and 4 were each 
split into two portions. One portion of each resin was then reacted with 10 equiv. of 
1,2-diaminobenzene in the presence of 1equiv. of 1,4-benzoquinone. After a reaction 
time of 5 hours, the products were cleaved from the resin and characterized by LC/MS, 
(m+H)+: 5a m/z 546, 5b m/z 618 (the predicted m/z is 545.25 and 617.33, respectively); 
(m+H)2+: 5a m/z 273, 5b m/z 309 (the corresponding predicted m/z are 272.63 and 
308.67). The crude yields obtained were approximately 65%. 
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Figure 2.6. Solid-phase synthesis of BI-(ߜ)-Orn-Gly2-His, where Gly2 (5a) can be 
substituted by Lys (5b). 
 
 
2.2.2 Compounds with an Amidinium Group (BI(+)-(ߜ)-Orn-Gly2-His) 
There are several reported pathways to convert nitriles to amidines, such as the 
classic/modified Pinner reaction16-17 and ammonia salts/ammonia conversion 
(ammonolysis).18 Unfortunately, applying these strategies to our resin-bound nitriles did 
not work. In addition to these strategies, Cesar et al. developed a new method to 
synthesize benzamidines on Wang resin. In this case, a benzonitrile was attached to the 
resin, followed by treatment with hydroxylamine to yield an amidoxime. The final 
conversion of amidoxime to amidine was realized through reacting the amidoxime with 
the reducing agent SnCl2·2H2O (1M solution in DMF).19 We employed this approach to 
our tripeptide-amidoxime benizimidazole conjugates. We found that approximately 80% 
of the benzimidazoles degraded during this step; however, the reduction proceeded well. 
These results indicated that an alternative strategy was necessary for this conversion. 
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Towards this end, it has been reported that 3,4-diaminobenzamidines can react with 
aldehydes to form benzimidazoles under the same conditions as 
3,4-diaminobenzonitrile.20 Given this, our new strategy involved conversion of 
3,4-diaminobenzonitrile to the corresponding amidoxime in solution, and then to 
condense this pre-formed amidoxime with the resin bound aldehyde to form the 
benzimidazole on solid support. Upon benzimidazole construction, final reduction of the 
amidoxime moiety by SnCl2·2H2O can be carried out on the solid support. The 
preparation of 3,4-diaminobenzamidoxime in solution is shown in Figure 2.7. 
  
              
Figure 2.7. The preparation of 3,4-diaminobenzamidoxime (7) in solution. 
 
The other two resin portions split from compounds 2 and 4 were used to couple with 
3,4-diaminobenzamidoxime in the above-described way. This reaction was monitored by 
cleaving a small amount of resin and conducting LC/MS characterization of the 
intermediate benzamidoxime. Further reduction of the resulting amidoximes were 
performed by adding 15 equiv. of SnCl2·2H2O (1M solution in DMF) to the reaction vials. 
The reaction proceeded under argon at 80Ԩ for 40h to allow the complete conversion 
(Figure 2.8).19 All products were cleaved from resin under standard conditions. Amidine 
conjugates were characterized by LC/MS at (m+H)+: 6a m/z 588, 6b m/z 659 (the 
predicted m/z are 587.28 and 658.36, respectively); (m+H)2+: 6a m/z 294, 6b m/z 330 (the 
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corresponding predicted m/z are 293.64 and 329.18). The crude yields obtained were 
50%. 
 
 
Figure 2.8. Solid-phase synthesis of BI(+)-(ߜ)-Orn-Gly2-His (where Gly2 (6a) can be 
substituted by Lys (6b)). 
 
2.3 Summary of Synthesis 
 
An efficient solid-phase synthesis protocol to generate phenyl-benzimidazole 
 
tripeptide conjugates was developed. The amino acids were coupled to Rink resins using  
 
standard protocols, followed by attachment to carboxybenzaldehyde under similar  
 
conditions. The resultant resin bound benzaldehydes were then mixed with  
 
pre-synthesized diaminobenzamidoximes, catalyzed by 1,4-benzoquinone, to form  
 
benzimidazole rings. The final step involved the reduction of resin-bound amidoxime by  
 
tin chloride. After resin cleavage and appropriate purification procedures, all the products  
 
were characterized by LC/MS. 
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2.4 Experimental Protocols 
 
 
 
2.4.1 General Considerations 
 
Solid phase syntheses were carried out in glass reactors with sintered frits or glass 
vials. Commercially available Fmoc-protected amino acids and 
4-(2',4'-dimethoxyphenyl-Fmoc-aminomethyl)-phenoxymethyl-polystyrene resins (Rink 
resin; 200-400 mesh) were purchased from Biochem and EMD. Other chemicals and 
solvents were reagent grade or better and were obtained from Sigma-Aldrich, Fisher 
Scientific, or other commercial sources.  
Silica gel chromatography was performed using a self-packed columns. 
 
Preparative HPLC purifications were carried out on a Varian 2200 series HPLC  
 
equipped with a C-18 semi preparative column. Mass spectra were determined on an  
 
Ailgent 1100 series LC/MS. 
 
 
2.4.2 Synthesis 
 
 
 
2.4.2.1 Solid-Phase Peptide Synthesis 
 
Tripeptide cores were synthesized using standard solid-phase Fmoc protocols. 2 g of  
 
resin was first allowed to swell in dichloromethane (DCM) for approximately 30 min. After  
 
rinsing this resin six times with N,N-dimethylformamide (DMF), the Fmoc protecting group  
 
was removed from the resin by mixing with a 30% piperidine/70% DMF solution for 15  
 
min. The resin was then rinsed alternatively with DMF and isopropanol (IPA). A Kaiser  
 
test was preformed to verify amine deprotection. In a separate Erlenmeyer flask, a 4-fold  
 
molar excess of Fmoc-protected amino acid, diisopropylcarbodiimide (DIC) and  
 
1-hydroxybenzotriazole (HOBt) was dissolved in DMF and then added to the resin and  
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mixed for approximately 1h. Following amino acid coupling, the resin was rinsed with  
 
DMF/IPA. A second Kaiser test was then performed to verify the presence of protected  
 
terminal amine, and thus successful coupling. Additional amino acids were added by  
 
repeating this procedure, beginning with Fmoc deprotection of the resin bound starting  
 
material. For peptide syntheses in this study, 2 g of resin was split into four portions,  
 
peptides 1 and 3 were cleaved off the resin by mixing with TFA and CH2Cl2 (1:1) solution  
 
for 3 h, after which the peptides were precipitated from cold methyl-tert butyl ether  
 
(MTBE). Centrifugation and lyophylization were then employed to concentrate and dry  
 
the crude peptide products.  
 
 
2.4.2.2 1,4-Carboxybenzaldehyde Coupling 
 
The remaining two portions of resin split from the original 2 g (see above) of starting  
 
resin Fmoc-(ߜ)-Orn-Gly/Lys-His (0.5 g) were used continued to couple with  
 
1,4-carboxybenzaldehyde after the deprotection of the ߜ-amine of ornithine. 5-fold molar  
 
excesses of 1,4-carboxybenzaldehyde (0.23 g) were mixed and activated with DIC (235  
 
ߤL), HOBt (0.2 g) and DIPEA (105 ߤL). The mixture was then added to the reactor vessel  
 
and bubbled with N2 overnight. The products 5a and 5b were rinsed with DMF/IPA and a  
 
Kaiser test was performed to assure the completion of the reaction. 
 
 
2.4.2.3 3,4-Diaminobenzamidoxime 
 
3,4-diaminobenzonitrile (2.4 mmol, 0.32 g) was dissolved in absolute EtOH (30 ml)  
 
and excess 50% aqueous hydroxylamine (1.0 ml) was added. The mixture was stirred for  
 
18h at room temperature, followed by refluxing for 3h and cooling to room temperature.  
 
Upon concentration under reduced pressure, silica gel (2 g) was added to form a powder  
 
for purification. The crude silica-bound product was loaded on a packed flash column and  
 
eluted with EtOAc/MeOH. Fractions were collected with 1-10% MeOH in EtOAc to give  
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7. The product was confirmed by LC/MS: (M+H)+ m/z 167 (the predicted m/z is 166.09)  
 
and the yield is approximately 95%. 
 
 
2.4.2.4 On-resin Benzimidazole Ring Construction 
 
Resin bound compounds 2 and 4 were split into two portions and mixed with  
 
pre-dissolved 3,4-diaminobenzene (10 equiv.) and 1, 4-benzoquinone (1 equiv.);  
 
3,4-diaminobenzamidoxime (compound 13) and 1,4-benzoquinone of the same ratio,  
 
respectively. The mixtures were heated to 60Ԩ and stirred for 16h in glass vials. The  
 
Products 5a and 6a were cleaved from the resin with TFA/CH2Cl2 (1:1). The brownish  
 
compounds were subjected to centrifugation, lyophylization and purification. The crude  
 
yields were approximately 65%. 
 
 
2.4.2.5 Amidoxime Reduction 
 
Resin bound amidoximes were transferred to glass vials and mixed with 15  
 
equiv. of SnCl2 (1 M solution in DMF). The reaction was conducted at 80Ԩ under  
 
argon for 40 h. Products were rinsed with DMF/IPA and cleaved from the resins under  
 
standard conditions. The same purification procedure as described in section 2.4.4 was  
 
employed to obtain 5b and 6b. The crude yields were approximately 50%. 
 
 
2.4.3 Purification 
 
C18 reversed-phase HPLC purification was performed for all products 
(BI-(ߜ)-Orn-Gly-His, BI-(ߜ)-Orn-Lys-His, BI(+)-(ߜ)-Orn-Gly-His, and BI(+)-(ߜ)-Orn-Lys-His). 
Conditions are listed as follow: Solvent A: H2O with 0.1% TFA, Solvent B: ACN with 0.1% 
TFA. Gradient: 0 min 95% A; 2 min 75% A; 5 min 60% A; 15 min 50% A; 17 min 100% B; 
19 min 95% A. 
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CHAPTER 3. DNA CLEAVAGE ACTIVITY OF PHENYL-BENZIMIDAZOLE 
 
MODIFIED GLY-GLY-HIS-DERIVED METALLOPEPTIDES 
 
 
                                                                
3.1 Overview 
 
Our design envisioned that the benzimidazole modified Gly-Gly-His-derived 
systems should exhibit increased DNA cleavage activity due to the presence of the 
benzimidazole moiety. Previous work1 indicated that the (ߜ)-Orn-Gly-His systems bind 
metals in a fashion identical to Gly-Gly-His system. In the present case, tripeptides with 
the phenyl-benzimidazole (+/-) functionalities may bind to metal slightly differently, but it 
is reasonable to assume that the tetradentate metal binding capabilities of the peptide 
should dominate metal binding. This investigation thus sought to determine if the 
phenyl-benzimidazole moieties (with or without amidines) attached to the metal binding 
domain influences metallopeptide-DNA interactions. Moreover, previous studies have 
found that Lys or Arg substituted Ni(II)·Gly1-Gly2-His metallopeptides possess enhanced 
levels of DNA cleavage activity relative to Ni(II)·Gly-Gly-His, therefore, the influence of 
Lys substitutions within the modified tripeptides was also examined. Thus, as listed in 
Figure 3.1, two groups of peptides were investigated based on the amino acid present at 
the Gly2 position: (1) Gly-Gly-His and its derivatives in contrast to (2) Gly-Lys-His and its 
derivatives. 
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                  A                                   B 
Figure 3.1. Structures of all compounds employed in DNA cleavage studies. Gly-Gly-His 
and its derivatives (A); Gly-Lys-His and its derivatives (B). 
 
 
 
3.2 Results and Discussion 
 
The ability of Ni(II)·Gly-Gly2-His (where Gly2 may be substituted by Lys) to  
 
mediate the conversion of supercoiled (form I) DNA to nicked circular (form II) DNA  
 
was assessed via the plasmid DNA cleavage assay discussed in Chapter 1. 
 
 
3.2.1 DNA Cleavage by Ni(II)·Gly-Gly-His and its Derivatives (1, 5a, 6a) 
 
To determine the effect of benzimidazoles (+/-) on the DNA cleavage activities of 
these systems, a comparison to Gly-Gly-His alone was carried out. The results from this 
side-by-side analysis are shown in Figure 3.2 with lanes 1-5 employed as controls, lanes 
6-8, lanes 9-11, and lanes 12-14 served as DNA cleavage reaction with Gly-Gly-His (1), 
BI-(ߜ)-Orn-Gly-His (5a) and BI(+)-(ߜ)-Orn-Gly-His (6a), respectively. As expected, given 
their structures, phenyl-benzimidazole modified Gly-Gly-His-derived compounds 
exhibited much greater DNA cleavage reactivity than the standard tripeptide Gly-Gly-His 
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alone. In particular, the amidinium derivative displayed an enhanced DNA cleavage 
ability with more pronounced bands of form II DNA (lane 12, 13, and 14). Therefore, the 
DNA strand scission efficiencies of the ligands in this series were determined to be: 
Ni(II)·BI(+)-(ߜ)Orn-Gly-His (6a) > Ni(II)·BI-(ߜ)Orn-Gly-His (5a) > Ni(II)·Gly-Gly-His (1).  
 
   1    2   3    4    5    6   7    8    9   10   11     12   13   14 
 
 
Figure 3.2. Agarose gel analysis of Ni(II)·Gly-Gly-His, Ni(II)·BI-(ߜ)-Orn-Gly-His and 
Ni(II)·BI(+)-(ߜ)-Orn-Gly-His induced cleavage of supercoiled ࢶࢷ174RF plasmid DNA. All 
reactions contained 30 ߤM DNA bp and 10mM sodium cacodylate buffer, PH 7.4. Lane 1, 
reaction control (DNA); lane 2, reaction control (DNA, 10 ߤM Ni2+, 10 ߤM KHSO5); lane 3, 
reaction control (DNA, 10 ߤM KHSO5, 12 ߤM GGH); lane 4, reaction control (DNA, 10 ߤM 
KHSO5, 12 ߤM BI-(ߜ)OGH); lane 5, reaction control (DNA, 10 ߤM KHSO5, 12 ߤM 
BI(+)-(ߜ)OGH); lane 6 (2.5 ߤM Ni2+, 2.5 ߤM KHSO5, 3 ߤM GGH); lane 7 (5 ߤM Ni2+, 5 ߤM 
KHSO5, 6 ߤM GGH); lane 8 (10 ߤM Ni2+, 10 ߤM KHSO5,12 ߤM GGH); lane 9 (2.5 ߤM Ni2+, 
2.5 ߤM KHSO5, 3 ߤM BI-(ߜ)OGH); lane 10 (5 ߤM Ni2+, 5 ߤM KHSO5, 6 ߤM BI-(ߜ)OGH); 
lane 11 (10 ߤM Ni2+, 10 ߤM KHSO5, 12 ߤM BI-(ߜ)OGH); lane 12 (2.5 ߤM Ni2+, 2.5 ߤM 
KHSO5, 2.5 ߤM BI(+)-(ߜ)OGH); lane 13 (5 ߤM Ni2+, 5 ߤM KHSO5, 6 ߤM BI(+)-(ߜ)OGH); 
lane 14 (10 ߤM Ni2+, 10 ߤM KHSO5, 12 ߤM BI(+)-(ߜ)OGH).  
 
 
The improved activity of Gly-Gly-His modified ligands may be attributed to three 
factors. First, the phenyl-benzimidazole group (with or without amidines) is the building 
block of many well-known DNA minor groove binders. The well-studied compound 
Hoechst 33258, which is mainly made up of two benzimidazole incorporated units in a 
head-to-tail manner. The X-ray crystallographic and NMR studies on complexes of 
Hoechst 33258 with A·T-containing oligonucleotides have shown that the ligand is bound 
in the minor groove, with the planar benzimidazole groups oriented parallel to the groove 
with each inner-facing nitrogen atom hydrogen bonding in a bifurcated manner to a pair of 
adjacent hydrogen-bond donors on the edge of the A·T base pairs.2 Thermodynamically 
speaking, the additional hydrogen bonding driving force may lead to stronger equilibrium 
binding to DNA. The incorporation of the flat benzimidazole group also provides more 
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points of contact within the minor groove floor of A·T rich region and leads to more 
favorable van der Waals interactions between DNA and the ligands. Studies found that 
the benzimidazole-derived compound showed an induced fit structure change to place 
functional groups in position to interact with bases at the floor of the groove.3-4 This 
‘flexibility’ feature makes benzimidazole moiety a very powerful tool which likely is 
working synergistically with our peptide complexation toward DNA binding and function to 
accelerate DNA cleavage.  
Second, the tethering of a phenyl-benzimidazole functional group to a metallopeptide 
may further stabilize the reactive complex formed via KHSO5. Previous 
M(II)·Xaa1-Xaa2-His metallopeptide-DNA cleavage studies have proposed that the active 
species responsible for deoxyribose damage is a peptide-bound Ni (III)-HO· or Ni(IV)=O, 
which is generated through the heterolytic splitting of the oxygen-oxygen bond present in 
KHSO5.5 The π system of the conjugated aromatic rings is able to delocalize electrons 
and help facilitate the stabilization of reactive high-valent metal ions, thus perhaps 
enhancing the rate of DNA cleavage relative to Ni(II)·Gly-Gly-His (1).  
Third, electrostatic interactions are likely to play an important role in the increased 
reactivity of Ni(II)·BI(+)-(ߜ)Orn-Gly-His (5b) vs. tripeptides alone. A net positive charge 
makes the complex more attractive to the polyanionic DNA helix and the increased local 
concentration of ligands in proximity to DNA allow the system to act more efficiently. 
Additionally, the amidine moiety is an important pharmacophore group in biologically 
active agents which is correlated with its ability to interact strongly with the DNA minor 
groove in A·T sequences.6 Therefore, the incorporated amidine group provides added 
stability to the bound complex. 
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3.2.2 DNA Cleavage by Ni(II)·Gly-Lys-His and its Derivatives (3, 5b, 6b) 
 
The affect of Lys substitution at the second position within the tripeptide ligand was 
examined also. Previous studies7-8 of unmodified tripeptides have confirmed that Lys 
substitutions lead to enhanced cleavage efficiency, likely due to the increased positive 
charge density on the peptide and the ability of Lys residue to stabilize the metal-peptide 
complexes.7 A comparison between Ni(II)·Gly-Gly-His (1) and Ni(II)·Gly-Lys-His (3) 
shown in Figure 3.3 supports this point of view.  
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Figure 3.3. Agarose gel analysis of Ni(II)·Gly-Gly-His and Ni(II)·Gly-Lys-His induced 
cleavage of supercoiled ࢶࢷ174RF plasmid DNA. All reactions contained 30 ߤM DNA bp 
and 10mM sodium cacodylate buffer, PH 7.4. lane 1, reaction control (DNA); lane 2, 
reaction control (DNA, 300 ߤM Ni2+, 300ߤM KHSO5); lane 3, reaction control (DNA, 300 
ߤM KHSO5, 360 ߤM GGH); lane 4, reaction control (DNA, 300 ߤM KHSO5, 360 ߤM GKH); 
lane 5 (100 ߤM Ni2+, 100 ߤM KHSO5, 120 ߤM GGH); lane 6 (200 ߤM Ni2+, 200 ߤM KHSO5, 
240 ߤM GGH); lane 7 (300 ߤM Ni2+, 300 ߤM KHSO5,360 ߤM GGH); lane 8 (100 ߤM Ni2+, 
100 ߤM KHSO5, 120 ߤM GKH); lane 9 (200 ߤM Ni2+, 200 ߤM KHSO5, 240 ߤM GKH); lane 
10 (300 ߤM Ni2+, 300 ߤM KHSO5, 360 ߤM GKH). 
 
 
Similarly, the attachment of a phenyl-benzimidazole group to the GKH ((ߜ)-OKH) 
tripeptide promoted DNA strand scission. With regard to the ligand containing an amidine 
group, interestingly, as illustrated in Figure 3.4, it appears that Ni(II)·BI(+)-(ߜ)Orn-Lys-His 
(6b) maintained a cleavage activity similar to that of Ni(II)·BI-(ߜ)Orn-Lys-His (5b). 
Compared to Ni(II)·BI-(ߜ)Orn-Lys-His (6a) which bears one positive charge, 
Ni(II)·BI(+)-(ߜ)Orn-Lys-His (6b) metallopeptide carries two positive charges. This 
observation implies that the addition of a Lys residue to the modified system is no longer 
a simple additive effect with regard to electrostatic forces. To further analyze the factors 
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that could potentially influence the reactivity of these ligands, a comparative experiment 
between the two groups was performed.  
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Figure 3.4. Agarose gel analysis of Ni(II)·Gly-Lys-His, Ni(II)·BI-(ߜ)-Orn-Lys-His and 
Ni(II)·BI(+)-(ߜ)-Orn-Lys-His induced cleavage of supercoiled ࢶࢷ174RF plasmid DNA. All 
reactions contained 30 ߤM DNA bp and 10mM sodium cacodylate buffer, PH 7.4. Lane 1, 
reaction control (DNA); lane 2, reaction control (DNA, 10 ߤM Ni2+, 10 ߤM KHSO5); lane 3, 
reaction control (DNA, 10 ߤM KHSO5, 12 ߤM GKH); lane 4, reaction control (DNA, 10 ߤM 
KHSO5, 12 ߤM BI-(ߜ)OKH); lane 5, reaction control (DNA, 10 ߤM KHSO5, 12 ߤM 
BI(+)-(ߜ)OKH); lane 6 (2.5 ߤM Ni2+, 2.5 ߤM KHSO5, 3 ߤM GKH); lane 7 (5 ߤM Ni2+, 5 ߤM 
KHSO5, 6 ߤM GKH); lane 8 (10 ߤM Ni2+, 10 ߤM KHSO5,12 ߤM GKH); lane 9 (2.5 ߤM Ni2+, 
2.5 ߤM KHSO5, 3 ߤM BI-(ߜ)OKH); lane 10 (5 ߤM Ni2+, 5 ߤM KHSO5, 6 ߤM BI-(ߜ)OKH); 
lane 11 (10 ߤM Ni2+, 10 ߤM KHSO5, 12 ߤM BI-(ߜ)OKH); lane 12 (2.5 ߤM Ni2+, 2.5 ߤM 
KHSO5, 2.5 ߤM BI(+)-(ߜ)OKH); lane 13 (5 ߤM Ni2+, 5 ߤM KHSO5, 6 ߤM BI(+)-(ߜ)OKH); 
lane 14 (10 ߤM Ni2+, 10 ߤM KHSO5, 12 ߤM BI(+)-(ߜ)OKH).  
 
 
As shown in Figure 3.5, Ni(II)·BI(+)-(ߜ)-Orn-Gly-His (5b) metallopeptide cleaved 
DNA to a much greater extent than Ni(II)·BI-(ߜ)-Orn-Gly-His (5a), Ni(II)·BI-(ߜ)-Orn-Lys-His 
(6a) and Ni(II)·BI(+)-(ߜ)-Orn-Lys-His (6b). The results suggest that the incorporation of an 
amidinium benzimidazole terminus optimizes the metallopeptide-DNA interaction as 
compared to the α-carbon substituent within the peptides resulting in increased DNA 
cleavage activity. With regard to Ni(II)·BI(+)-(ߜ)-Orn-Lys-His (6b) which is equipped with 
both a terminal amidine and an α-carbon Lys substituent, perhaps the coexistence of 
them decreases the flexibility of the complex and results in conformations with less 
favorable metallopeptide-DNA orientations. The result also indicates that the inclusion of 
a Lys residue at the second position within the modified ligand (Ni(II)·BI-(ߜ)-Orn-Lys-His) 
enhances DNA cleavage reactivity relative to the Ni(II)·BI-(ߜ)-Orn-Gly-His (5a) 
metallopeptide. 
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Figure 3.5. Agarose gel analysis of Ni(II)·BI-(ߜ)-Orn-Gly-His, Ni(II)·BI(+)-(ߜ)-Orn-Gly-His, 
Ni(II)·BI-(ߜ)-Orn-Lys-His and Ni(II)·BI(+)-(ߜ)-Orn-Lys-His induced cleavage of supercoiled 
ࢶࢷ174RF plasmid DNA. All reactions contained 30 ߤM DNA bp and 10mM sodium 
cacodylate buffer, PH 7.4. lane 1, reaction control (DNA); lane 2, reaction control (DNA, 5 
ߤM Ni2+, 5 ߤM KHSO5); lane 3, reaction control (DNA, 5 ߤM KHSO5, 6 ߤM BI-(ߜ)OGH); 
lane 4, reaction control (DNA, 5 ߤM KHSO5, 6 ߤM BI(+)-(ߜ)OGH); lane 5, reaction control 
(DNA, 5 ߤM KHSO5, 6 ߤM BI-(ߜ)OKH); lane 6 reaction control (DNA, 5 ߤM KHSO5, 6 ߤM 
BI(+)-(ߜ)OKH); lane 7 (5 ߤM Ni2+, 5 ߤM KHSO5, 6 ߤM BI-(ߜ)OGH); lane 8 (5 ߤM Ni2+, 5 ߤM 
KHSO5, 6 ߤM BI(+)-(ߜ)OGH); lane 9 (5 ߤM Ni2+, 5 ߤM KHSO5, 6 ߤM BI-(ߜ)OKH); lane 10 
(5 ߤM Ni2+, 5 ߤM KHSO5, 6 ߤM BI(+)-(ߜ)OKH).  
 
 
3.3 Conclusions 
 
The DNA cleavage studies described in this chapter demonstrated that  
(1) tripeptides with phenyl-benzimidazole functionalities have enhaced DNA cleavage 
and (2) the phenyl-benzimidazole-modified Gly-Gly-His-derived metallopeptides 
exhibited an increased DNA strand scission efficiency relative to the standard 
Ni(II)·Gly-Gly-His metallopeptide. In addition, a side by side comparison of 
Ni(II)·BI-(ߜ)Orn-Gly-His, Ni(II)·BI(+)-(ߜ)Orn-Gly-His, Ni(II)·BI-(ߜ)Orn-Lys-His, and 
Ni(II)·BI(+)-(ߜ)Orn-Lys-His revealed that the amidinium benzimidazole moiety contributes 
to DNA cleavage activity. However, more techniques, such as FID (fluorescence 
intercalator displacement) and molecular dynamic simulations need to be employed to 
thoroughly elucidate the DNA binding modes and site selectivities of these ligands. 
The development of N-terminal modified metallopeptides could further our  
 
understanding of protein- and small molecule-DNA interactions and assist in the redesign  
 
of naturally-occurring antitumor agents. Using these methods, other documented DNA  
 
recognition moieties in addition to benzimidazole could be employed to impart enhanced  
 
DNA site selectivity to the metallopeptides. Meanwhile, the utilization of other amino  
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acids within the peptide portion may increase the reactivity of the complexes. For  
 
example, Met, Ser and Thr in the Gly2 position proved to result in increased DNA  
 
cleavage activity.9 In fact, it may be possible in the future to build a combinatorial library  
 
of these systems by tuning the intrinsic properties of these modified metallopeptides. 
 
 
3.4 Experimental Protocols 
 
DNA cleavage reactions were prepared by first pre-incubating modified peptides with 
Ni(OAc)2 at a ratio of metal to metal binding site of 1:1.2 in 10 mM sodium cacodylate 
buffer (pH 7.4) to form the metallopeptide complex. This was followed by the addition of 
ࢶX174 RF DNA (30 ߤM base pair final concentration). After incubating the reaction 
mixtures for 10 min at room temperature, cleavage reactions were initiated upon the 
addition of KHSO5 in an amount equimolar to Ni(II) and quenched after one minute by 
adding an EDTA containing loading buffer. Reaction aliquots were loaded onto 0.9% 
agarose gels containing 5 ߤg/ml ethidium bromide and electrophoresed in TAE buffer at 
60 volts for 2 h and visualized using a UV transilluminator. 
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